Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

被引：0

作者：

Cottereau, Anne Segolene ^{[1
]}

Rebaud, Louis ^{[2
]}

Trotman, Judith ^{[3
]}

Feugier, Pierre ^{[4
]}

Nastoupil, Loretta J. ^{[5
]}

Bachy, Emmanuel ^{[6
]}

Flinn, Ian W. ^{[7
]}

Haioun, Corinne ^{[8
]}

Ysebaert, Loic ^{[9
]}

Bartlett, Nancy L. ^{[10
]}

Tilly, Herve ^{[11
]}

Casasnovas, Rene-Olivier ^{[12
]}

Ricci, Romain ^{[13
]}

Portugues, Cedric ^{[14
]}

Buvat, Irene ^{[15
]}

Meignan, Michel ^{[16
,17
]}

Morschhauser, Franck ^{[18
]}

机构：

[1] Cochin Univ Hosp, AP HP, Dept Nucl Med, Paris, France

[2] Inst Curie, Lab Imagerie Translat Oncol, U1288 Inserm, Paris, France

[3] Concord Hosp, Dept Haematol, Concord, Australia

[4] Univ Hosp Nancy, Hematol Dept, Vandoeuvre Les Nancy, France

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[6] Lyon Sud Univ Hosp, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[8] Univ Paris Est Creteil UPEC, Lymphoid Malignancies Dept, Henri Mondor Univ Hosp Assistance, Assistance Publ Hop Paris AP HP, Creteil, France

[9] Inst Univ Canc Toulouse Oncopole, Hematol Dept, Toulouse, France

[10] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[11] Ctr Henri Becquerel, Rouen, France

[12] CHU Dijon Bourgogne, Hematol Clin, Dijon, France

[13] Lymphoma Acad Res Org, LYSARC, Creteil, France

[14] Ctr Hosp Lyon Sud, Lymphoma Acad Res Org, LYSARC, Lyon, France

[15] Univ Paris Saclayr, Inst Curie, LITO Lab, UMR 1288 Inserm, Orsay, France

[16] CHU Henri Mondor, Creteil, France

[17] LYSA, Paris, France

[18] CHU Lille, Serv Malad Sang, Lille, France

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159207

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6474 / 6476

页数：3

共 21 条

[21] JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy.
O'Reilly, Eileen Mary
Walker, Christopher
Clark, Jason
Brill, Kimberli J.
Dawkins, Fitzroy W.
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 →